Ingrid Boere

6.1k total citations
72 papers, 1.0k citations indexed

About

Ingrid Boere is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Ingrid Boere has authored 72 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Reproductive Medicine, 32 papers in Oncology and 32 papers in Obstetrics and Gynecology. Recurrent topics in Ingrid Boere's work include Ovarian cancer diagnosis and treatment (33 papers), Endometrial and Cervical Cancer Treatments (28 papers) and Cancer Risks and Factors (13 papers). Ingrid Boere is often cited by papers focused on Ovarian cancer diagnosis and treatment (33 papers), Endometrial and Cervical Cancer Treatments (28 papers) and Cancer Risks and Factors (13 papers). Ingrid Boere collaborates with scholars based in Netherlands, United States and Italy. Ingrid Boere's co-authors include Frédéric Amant, Christianne Lok, Kristel Van Calsteren, Petronella O. Witteveen, Tineke Vandenbroucke, M Halaška, Mina Mhallem Gzirí, Henriëtte S. de Bruijn, Dominic J. Robinson and Henricus J. C. M. Sterenborg and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Ingrid Boere

67 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ingrid Boere Netherlands	19	555	233	210	208	198	72	1.0k
Christianne Lok Netherlands	22	625 1.1×	398 1.7×	481 2.3×	289 1.4×	360 1.8×	90	1.7k
Paula S. Lee United States	23	310 0.6×	582 2.5×	448 2.1×	160 0.8×	203 1.0×	45	1.4k
Michael Eichbaum Germany	19	355 0.6×	195 0.8×	187 0.9×	122 0.6×	30 0.2×	61	965
Catherine Shannon Australia	20	704 1.3×	141 0.6×	171 0.8×	157 0.8×	79 0.4×	48	1.2k
Jacob Korach Israel	24	567 1.0×	565 2.4×	886 4.2×	110 0.5×	150 0.8×	107	1.6k
Taymaa May Canada	17	259 0.5×	457 2.0×	662 3.2×	131 0.6×	63 0.3×	94	1.1k
Jae Yun Song South Korea	19	233 0.4×	300 1.3×	391 1.9×	178 0.9×	32 0.2×	80	1.1k
Eugenia Girda United States	13	306 0.6×	191 0.8×	147 0.7×	58 0.3×	19 0.1×	55	769
Joshua P. Kesterson United States	18	235 0.4×	225 1.0×	218 1.0×	76 0.4×	26 0.1×	60	779
N.P. Koper Netherlands	12	583 1.1×	63 0.3×	231 1.1×	42 0.2×	80 0.4×	20	1.0k

Countries citing papers authored by Ingrid Boere

Since Specialization

Citations

This map shows the geographic impact of Ingrid Boere's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingrid Boere with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingrid Boere more than expected).

Fields of papers citing papers by Ingrid Boere

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingrid Boere. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingrid Boere. The network helps show where Ingrid Boere may publish in the future.

Co-authorship network of co-authors of Ingrid Boere

This figure shows the co-authorship network connecting the top 25 collaborators of Ingrid Boere. A scholar is included among the top collaborators of Ingrid Boere based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingrid Boere. Ingrid Boere is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boere, Ingrid, et al.. (2025). Quality of life and survival in patients with uterine carcinosarcoma: A tertiary center observational study. Gynecologic Oncology Reports. 57. 101679–101679.

Lindemann, Kristina, Zhongqiu Lin, Shin Nishio, et al.. (2025). TroFuse-020/GOG-3101/ENGOT-Cx20: A Phase 3, Randomised, Active-Controlled, Open-Label, Multicentre Study Comparing Sacituzumab Tirumotecan Monotherapy Vs Treatment Of Physician’s Choice As Second-Line Treatment For Recurrent Or Metastatic Cervical Cancer. International Journal of Gynecological Cancer. 35(2). 100497–100497. 1 indexed citations

Boere, Ingrid, Ruben Boers, Joachim Boers, et al.. (2025). Genome-wide cell-free DNA methylation profiling in advanced stage ovarian cancer. Are we looking at the tumor or the patient's immune response to the tumor?. Cancer Treatment and Research Communications. 43. 100903–100903.

Xu, Tong, Miriam Teeuwssen, Wenjie Sun, et al.. (2024). Tropomyosin1 isoforms underlie epithelial to mesenchymal plasticity, metastatic dissemination, and resistance to chemotherapy in high-grade serous ovarian cancer. Cell Death and Differentiation. 31(3). 360–377. 5 indexed citations

Heimovaara, Joosje H., Christianne Lok, M Halaška, et al.. (2024). Maternal death by cancer in pregnancy: A descriptive study of the International Network on Cancer, Infertility and Pregnancy. BJOG An International Journal of Obstetrics & Gynaecology. 131(12). 1694–1704. 1 indexed citations

Auranen, Annika, Lyndsay Willmott, David Cibula, et al.. (2024). 37MO Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: Overall survival (OS) by MMR status and molecular subgroups. ESMO Open. 9. 103537–103537. 3 indexed citations

Mirza, Mansoor Raza, Destin Black, Antonella Savarese, et al.. (2024). 38MO Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial. ESMO Open. 9. 103538–103538. 6 indexed citations

Boers, Ruben, Jean Helmijr, Corine M. Beaufort, et al.. (2024). Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer Patients. Genes. 15(6). 750–750. 4 indexed citations

Ghamande, Sharad, Lars Hanker, Destin Black, et al.. (2024). Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Gynecologic Oncology. 190. S6–S6. 11 indexed citations

10.

Mirza, Mansoor Raza, Sudarshan Sharma, Jørn Herrstedt, et al.. (2023). 740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Annals of Oncology. 34. S507–S507. 20 indexed citations

11.

Gorp, Toon Van, Renaud Sabatier, Gottfried E. Konecny, et al.. (2023). #1015 Mirvetuximab soravtansine demonstrates longer overall survival and progression-free survival by prior lines of therapy vs chemotherapy in platinum-resistant ovarian cancer and high folate receptor alpha expression in the MIRASOL trial. A29.2–A30. 2 indexed citations

12.

Mirza, Mansoor Raza, Dana M. Chase, Brian M. Slomovitz, et al.. (2023). Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (LBA 11). Gynecologic Oncology. 176. S43–S44. 2 indexed citations

13.

Mirza, Mansoor Raza, Mark S. Shahin, Matthew A. Powell, et al.. (2023). Patient-reported outcomes (PROs) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab (D) plus carboplatin/paclitaxel (CP) compared with CP in the ENGOT-EN6/GOG3031/RUBY trial.. JCO Oncology Practice. 19(11_suppl). 332–332. 1 indexed citations

14.

Heemskerk‐Gerritsen, Bernadette A. M., Antoinette Hollestelle, Christi J. van Asperen, et al.. (2022). Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study. PLoS ONE. 17(9). e0275015–e0275015. 1 indexed citations

15.

Doorn, Leni van, Wendy M. van der Deure, Esther Oomen‐de Hoop, et al.. (2021). Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel. Cancers. 13(15). 3915–3915. 2 indexed citations

16.

Gerwen, Mathilde van, Charlotte Maggen, Elyce Cardonick, et al.. (2021). Association of Chemotherapy Timing in Pregnancy With Congenital Malformation. Obstetrical & Gynecological Survey. 76(12). 732–733. 3 indexed citations

17.

Maggen, Charlotte, Christianne Lok, Mathilde van Gerwen, et al.. (2021). Maternal and Neonatal Outcome after the Use of G-CSF for Cancer Treatment during Pregnancy. Cancers. 13(6). 1214–1214. 10 indexed citations

18.

Boere, Ingrid, Christianne Lok, Tineke Vandenbroucke, & Frédéric Amant. (2017). Cancer in pregnancy: safety and efficacy of systemic therapies. Current Opinion in Oncology. 29(5). 328–334. 19 indexed citations

19.

Amant, Frédéric, Tineke Vandenbroucke, Magali Verheecke, et al.. (2016). Pediatric Outcome After Maternal Cancer Diagnosed During Pregnancy. Obstetrical & Gynecological Survey. 71(3). 144–146. 6 indexed citations

20.

Burg, M.E.L. van der, Wendy Onstenk, Ingrid Boere, et al.. (2014). Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. European Journal of Cancer. 50(15). 2592–2601. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact